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The debate over whether activated Ras can regulate
phosphoinositide-specific phospholipase C (PLC) has
been contentious and at times heated. The argument
may be resolved by the recent identification of a novel
Ras-regulated PLC, but some unexpected properties of
this protein are sure to stimulate further controversy.
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The Ras proteins are small GTP-binding proteins that
have achieved notoriety as products of genes that are found
mutated in approximately 15% of all human tumours [1].
In cells harbouring a Ras oncogene, the Ras oncoprotein is
locked in the GTP-bound active conformation as a result
of a defective GTPase activity. In this state, Ras is consti-
tutively active and can transmit signals for proliferation,
differentiation and oncogenesis in the absence of cellular
stimulation. To fully appreciate how Ras signals down-
stream, there is a need to identify the proteins that interact
directly with the active GTP-bound form of Ras.
Among the pathways that signal downstream from
activated Ras, the one that starts with the serine-threonine
kinase Raf and follows with activation of the ERK mitogen-
activated protein (MAP) kinases, remains of key impor-
tance for many facets of Raf biology. However, it is now
well appreciated that Ras uses a multitude of downstream
effectors, in addition to Raf, to cause its diverse biological
actions. The biochemically and genetically best-charac-
terised of these are the phosphoinositide 3-kinases (PI 3-
kinases) and members of the Ral guanine nucleotide
exchange factor (RalGEF) family (reviewed in [2]). Results
reported recently suggest that this select group has now
been joined by phosphoinositide-specific phospholipase C
epsilon (PLCε) — a novel PLC that binds to, and is regu-
lated by, activated Ras [3–6].
Phosphoinositide-specific PLCs are a family of enzymes
that regulate the hydrolysis of the inner plasma membrane
lipid phosphatidylinositol 4,5-bisphosphate (PIP2) [7].
This reaction yields two intracellular second messengers,
diacylglycerol and inositol 1,4,5-trisphosphate (IP3), which
induce, respectively, activation of protein kinase C and the
release of internally stored Ca2+. Prior to the discovery of
PLCε, ten mammalian PLC isoforms had been identified:
PLCβ1–4, PLCδ1–4 and PLCγ1–2, all of which contain a
δ-like core, composed of two regions of high sequence
similarity (X and Y) which together constitute the PLC
catalytic domain, a pleckstrin homology (PH) domain, an
EF-hand domain, and a C2 domain (Figure 1) [7]. Besides
this δ-like core, the β isozymes have carboxy-terminal
extensions of around 400 residues, and the γ isozymes have
an insertion of about 500 residues between the two halves
of the catalytic domain. These structural differences are
linked to the distinct mode of regulation for each isozyme:
association with heterotrimeric G proteins of the Gq
family stimulates the β isozymes, whereas the γ isozymes,
which contains Src homology (SH2 and SH3) domains, are
activated by receptor or cytosolic tyrosine kinases. The
mechanism of regulation of PLCδ is less clear, but changes
in intracellular Ca2+ may be involved [7].
Sequence analysis of human [4,5], rat [6] and Caenorhabdi-
tis elegans [3] forms of PLCε showed that, whereas the cen-
trally located X and Y domains and the C2 domain are
highly conserved in this isozyme, the PH and EF-hand
domains are absent. At the molecular level, however, the
diagnostic features of PLCε are the presence of an amino-
terminal Ras GTP exchange factor domain and two
carboxy-terminal Ras-association domains, RA1 and RA2.
This unique structural organisation clearly suggests that
PLCε represents a novel fourth class of mammalian PLC
isoforms. Interestingly, the human PLCε described by
Lopez et al. [4] has an amino-terminal deletion of approxi-
mately 304 amino acids compared with the one cloned by
Song et al. [5]. Although this deletion does not remove any
of the functional domains, it does suggest the existence of
at least two splice variants of human PLCε.
From the degree of conservation with other Ras effectors,
one would predict that the RA domains of PLCε should
bind activated Ras. Indeed, the RA2 domain of PLCε was
found to bind Ras in a GTP-dependent manner, with an
affinity comparable to the binding of Ras to Raf-1 [6].
Furthermore, the RA2 domain is typical of other Ras-
binding domains in that it interacts with Ras through
residues predicted by structural and functional analysis to
be important in other Ras effectors [8]. For instance, muta-
tion of a single lysine residue critical for Ras binding to
other RA domains [8] — K2150 in rat PLCε — inhibits Ras
binding to the RA2 domain [6]. Finally, like its binding to
other Ras effectors, Ras binds to the RA2 domain of PLCε
through its effector domain, as mutations in this region —
such as T35S and Y40C — inhibit binding [6].
So clearly the RA2 domain of PLCε binds to activated Ras.
But what is the significance of this interaction in terms of
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the ability of PLCε to hydrolyse PIP2? To address this
question, Kelley et al. [6] examined the activity of PLCε in
COS-7 cells in the presence or absence of a constitutively
active mutant form of H-Ras. They not only found that
the mutant Ras markedly stimulated the PLC activity of
PLCε, but observed a complete correlation between the
mutational effects on Ras binding to the RA2 domain and
the resulting ability of Ras to stimulate the enzymatic
activity of PLCε [6]. Such an elegant analysis provides
strong evidence that the binding of activated Ras to the
RA2 domain results in activation of PLCε. The criteria for
being a genuine Ras effector — namely the ability to bind
to and be regulated by activated Ras — are thus fulfilled
by PLCε. (Note, for those researchers using the various
Ras effector mutants to specifically activate a given Ras
effector, it is important to consider that the E37G mutant
stimulates PLCε and should therefore not be considered
as specifically activating RalGDS; furthermore, the D38N
mutant — up to now considered a universal inhibitor —
significantly activates PLCε [6].)
The precise mechanism by which Ras activates its effec-
tors is currently unclear. For instance, the mechanism of
Raf-1 activation is complex, requiring the Ras-induced
translocation of Raf-1 to the plasma membrane, induc-
tion of a conformational change and modification by phos-
phorylation (see [9] for a current model). For the purposes
of this discussion, however, it is notable that evidence is
accumulating to suggest that Ras activates Raf-1 by
binding to two Ras-binding domains [10,11]. In addition
to the high-affinity RA domain, Raf-1 also has an adja-
cent cysteine-rich domain (CRD) that binds Ras in a
GTP-independent manner. It has been proposed that Ras
interaction with this domain is critical for Ras activation of
Raf-1 — a similar requirement for dual Ras binding sites
appears necessary for Ras activation of yeast adenylyl
cyclase [12].
Given that PLCε has two RA domains, can a similar model
account for the Ras-mediated activation of PLCε? A
number of observations are consistent with this. First, for
Ras to activate PLCε it must be post-translationally modi-
fied [6]. Secondly, activated Ras can induce the plasma
membrane translocation of cytosolic PLCε [5]. Finally, the
RA1 domain of PLCε is not only similar to the CRD of
Raf-1, in that it binds Ras with a low affinity and in a
GTP-independent manner [6], but it is also required for
Ras-mediated activation of PLCε [6]. Thus, the mecha-
nism for Ras activation of PLCε is certainly complex,
involving translocation and/or activation via the tandem
RA domains.
Activated Ras may not, however, be the sole regulator of
PLCε. As with a number of other Ras effectors, the RA2
domain of PLCε also binds the GTP-bound form of the
Ras-related protein Rap1A — this results from Rap1A
having an effector domain virtually identical to that of Ras
[5,6]. Although this interaction may target PLCε to a
perinuclear localisation, rather than the plasma membrane
[5], its physiological relevance remains to be established.
Lopez et al. [4] also suggest that PLCε is one of the few
effectors for the G12/13 family of heterotrimeric G-pro-
teins. These highly oncogenic G proteins — a GTPase
deficient mutant of Gα12 can fully transform NIH3T3
Figure 1
A diagrammatic representation of the newly
expanded family of mammalian PLC isozymes.
The various molecular domains, and the
possibility of two human PLCε splice variants
(tentatively termed PLCε1 and PLCε2) are
discussed further in the text. 
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cells [13] — are currently poorly characterised. Gα12 is
known to stimulate c-Jun via activation of Ras, but the
mechanism by which Gα12 activates Ras is unknown [14].
Given that PLCε contains an amino-terminal Ras GTP
exchange factor domain, it is tempting to speculate that
PLCε may act as a direct link between Gα12 and Ras.
Indeed, expression of PLCε promotes Ras activation by
the exchange of GTP for bound GDP [4], but it is unclear
whether Gα12 can directly stimulate this activity.
The ability of PLCε to activate Ras raises the possibility
that PLCε may positively regulate its own PLC activity. If
this is the case, how can such a feedforward cycle be regu-
lated? Although there are a number of possible mecha-
nisms, it is tempting to speculate about the involvement of
GAP1m and GAP1IP4BP. These GTPase-activating pro-
teins (GAPs) switch-off Ras signalling by stimulating the
intrinsic Ras GTPase activity, thereby converting Ras
from the active GTP-bound to the inactive GDP-bound
conformation [15]. As the GAP activities of GAP1m and
GAP1IP4BP are stimulated by Gα12 and inositol 1,3,4,5-
tetrakisphosphate (IP4), respectively [16,17], it is an
intriguing possibility that they may be involved in nega-
tively regulating PLCε. (Note that IP4 is a second messen-
ger generated by the phosphorylation of IP3, one of the
products of PLCε-stimulated PIP2 hydrolysis.)
However, the really important question remains: how does
PLCε fit in with our understanding of Ras signalling?
Although there is a clearly established linked between Ras
and PI 3-kinases [1,2] — the other major inositol-based sig-
nalling pathway in cells — relatively little information is
available on a link between Ras and PLC. Back in 1986, the
groups of Lewis Cantley [18] and Mike Wakelam [19]
reported independent evidence that an increase in the level
of inositol phosphates could be detected in cells expressing
activated Ras. This result — indicative of an increase in
PLC activity — led the authors to suggest that activated
Ras lay upstream of PLC [18–20]. At the time, these data
were viewed as extremely controversial, and they subse-
quently have been largely ignored (see for example [21,22]).
The identification of PLCε rekindles interest in these data,
and may in fact validate the basic conclusion drawn by
Cantley and Wakelam. Irrespective of this, the really impor-
tant point is that the characterisation of PLCε as a Ras effec-
tor has again placed PLC in the spotlight of Ras biology. As
with other Ras effectors, the next crucial step is to establish
the role of PLCε in transmitting signals from activated Ras
through to changes in proliferation, differentiation and
oncogenesis. As Ras most likely uses distinct sets of effec-
tors in a combinatorial fashion to effect its diverse biological
actions, this will be an exciting, but challenging problem. 
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